Premium
Metabolic syndrome and prostate cancer
Author(s) -
Glode L. Michael
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23511
Subject(s) - medicine , prostate cancer , metabolic syndrome , bicalutamide , androgen deprivation therapy , oncology , disease , diabetes mellitus , hormone therapy , type 2 diabetes , cancer , endocrinology , gynecology , breast cancer , androgen receptor
The metabolic syndrome (MetS) was first proposed as a clinical entity in 1988 and has been popularized by numerous health organizations as a way of identifying patients at increased risk for coronary heart disease or type II diabetes. The numerous definitions for MetS has made it somewhat difficult for practicing physicians to adopt a standard and then apply it to behavioral modification and/or pharmacologic therapy for their patients. In this issue of Cancer , Smith et al. performed a prospective analysis of some components of MetS in 26 men with locally advanced or recurrent prostate cancer who were treated with 1 year of leuprolide in addition to 1 month of bicalutamide at the time of the initiation of gonadotropin‒releasing hormone agonist therapy. Some differences between classic MetS and the androgen deprivation syndrome were demonstrated.